Imaging of the brain serotonin transporters (SERT) with 18F-labelled fluoromethyl-McN5652 and PET in humans

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 39, Issue 6, 2012, Pages 1001-1011

  Hesse, Swen ^a,b   Brust, Peter ^c   Mäding, Peter ^c   Becker, Georg Alexander ^a   Patt, Marianne ^a   Seese, Anita ^a   Sorger, Dietlind ^a   Zessin, Jörg ^c   Meyer, Philipp M ^a   Lobsien, Donald ^a   Laudi, Sven ^a   Habermann, Bernd ^a   Füchtner, Frank ^c   Luthardt, Julia ^a   Bresch, Anke ^a   Steinbach, Jörg ^c   Sabri, Osama ^a  

^a UNIVERSITY OF LEIPZIG   (Germany)

^b UNIVERSITY HOSPITAL LEIPZIG   (Germany)

^c INSTITUTE OF ION BEAM PHYSICS AND MATERIALS RESEARCH   (Germany)

Author keywords

18F; PET; Positron emission tomography; Serotonin transporter

Indexed keywords

F ME MCN 5652 FLUORINE F 18; RADIOPHARMACEUTICAL AGENT; SEROTONIN TRANSPORTER; TRACER; UNCLASSIFIED DRUG;

ABSENCE OF SIDE EFFECTS; ADULT; AMYGDALOID NUCLEUS; ANTERIOR CINGULATE; ARTICLE; BLOOD SAMPLING; BRAIN; BRAIN CORTEX; CAUDATE NUCLEUS; CEREBELLUM; CLINICAL ARTICLE; DRUG BLOOD LEVEL; DRUG PROTEIN BINDING; DRUG UPTAKE; FEMALE; HIPPOCAMPUS; HUMAN; IMAGE PROCESSING; IN VIVO STUDY; INSULA; MALE; MESENCEPHALON; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEUS ACCUMBENS; PONS; POSITRON EMISSION TOMOGRAPHY; PREFRONTAL CORTEX; PROTEIN LOCALIZATION; PUTAMEN; RAPHE MAGNUS NUCLEUS; THALAMUS;

ADULT; BINDING SITES; BIOLOGICAL TRANSPORT; BLOOD PROTEINS; BRAIN; FEMALE; FLUORINE RADIOISOTOPES; HUMANS; ISOQUINOLINES; MALE; POSITRON-EMISSION TOMOGRAPHY; REFERENCE STANDARDS; SAFETY; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS;

EID: 84862654297     PISSN: 16197070     EISSN: 16197089     Source Type: Journal    
DOI: 10.1007/s00259-012-2078-z     Document Type: Article

References (25)

1. 3H]imipramine J Pharmacol Exp Ther 242 364 371 3475452
2. S Hesse H Barthel J Schwarz O Sabri U Müller 2004 Advances in in vivo imaging of serotonergic neurons in neuropsychiatric disorders Neurosci Biobehav Rev 28 547 563 15527862 10.1016/j.neubiorev.2004.08.004 1:CAS:528:DC%2BD2cXpsVOmu70%3D
3. JH Meyer 2007 Imaging the serotonin transporter during major depressive disorder and antidepressant treatment J Psychiatry Neurosci 32 86 102 17353938
4. S Hesse U Müller T Lincke H Barthel T Villmann MC Angermeyer, et al. 2005 Serotonin and dopamine transporter imaging in patients with obsessive-compulsive disorder Psychiatry Res 140 63 72 16213689 10.1016/j.pscychresns.2005.07.002 1:CAS:528:DC%2BD2MXht1yltLnP
5. UF Bailer GK Frank SE Henry JC Price CC Meltzer C Becker, et al. 2007 Serotonin transporter binding after recovery from eating disorders Psychopharmacol (Berl) 195 315 324 10.1007/s00213-007-0896-7 1:CAS:528:DC%2BD2sXhtlWktbzM
6. Z Szabo T Owonikoko M Peyrot J Varga WB Mathews HT Ravert, et al. 2004 Positron emission tomography imaging of the serotonin transporter in subjects with a history of alcoholism Biol Psychiatry 55 766 771 15039007 10.1016/j.biopsych.2003.11.023 1:CAS:528:DC%2BD2cXisVegs7w%3D
7. UD McCann Z Szabo M Vranesic M Palermo WB Mathews HT Ravert 2008 Positron emission tomographic studies of brain dopamine and serotonin transporters in abstinent (±)3,4-methylenedioxymethamphetamine ("ecstasy") users: relationship to cognitive performance Psychopharmacology (Berl) 200 439 450 10.1007/s00213-008-1218-4 1:CAS:528:DC%2BD1cXhtFOjsbzK
8. 11C](+)McN5652 as a radiotracer for imaging serotonin uptake sites with PET Life Sci 53 883 892 8366755 10.1016/0024-3205(93)90440-E 1:CAS:528:DyaK3sXmsVCmsLw%3D
9. 11C-labeled 2-(phenylthio)araalkylamines J Med Chem 43 3103 3110 10956218 10.1021/jm000079i 1:CAS:528:DC%2BD3cXltFCisrc%3D
10. 11C]DASB and positron emission tomography in humans: modeling considerations J Cereb Blood Flow Metab 27 205 217 16736050 10.1038/sj.jcbfm.9600329 1:CAS:528:DC%2BD2sXptleqsA%3D%3D
11. 11C-DASB in healthy humans Synapse 55 164 175 15605360 10.1002/syn.20105 1:CAS:528:DC%2BD2MXht1CgtLk%3D
12. 18F]-ADAM in rats and monkeys Eur J Nucl Med Mol Imaging 37 545 555 19820930 10.1007/s00259-009-1281-z 1:CAS:528:DC%2BC3cXhvFKgsbo%3D
13. JS Stehouwer MM Goodman 2009 Fluorine-18 radiolabeled PET tracers for imaging monoamine transporters: dopamine, serotonin, and norepinephrine PET Clin 4 101 128 20216936 10.1016/j.cpet.2009.05.006
14. Y Huang MQ Zheng JM Gerdes 2010 Development of effective PET and SPECT imaging agents for the serotonin transporter: has a twenty-year journey reached its destination? Curr Top Med Chem 10 1499 1526 20583995 1:CAS:528: DC%2BC3cXht1ahtr3N
15. 18F]fluoromethyl)-(+)-McN5652 as a potential PET radioligand for the serotonin transporter Nucl Med Biol 28 857 863 11578908 10.1016/S0969-8051(01)00248-7 1:CAS:528:DC%2BD3MXntV2htbs%3D
16. 18F]fluoromethyl)-(+)-McN5652 Eur Neuropsychopharmacol 13 387 397 12957338 10.1016/S0924-977X(03)00039-7 1:CAS:528: DC%2BD3sXmvVOhtb8%3D
17. 18F]fluoromethyl-(+)-McN5652, a PET tracer for the serotonin transporter: evaluation in rats Synapse 47 45 53 12422372 10.1002/syn.10150
18. 18F]fluoromethyl)-(+) -McN5652 Synapse 47 143 151 12454952 10.1002/syn.10163 1:CAS:528: DC%2BD3sXlt1ChsA%3D%3D
19. 18F] fluoromethyl)-(+)-McN5652 Neuropsychopharmacology 28 2010 2019 12931143 10.1038/sj.npp.1300281 1:CAS:528:DC%2BD3sXot12gsL8%3D
20. S Hesse K Stengler R Regenthal M Patt GA Becker A Franke, et al. 2011 The serotonin transporter availability in untreated early-onset and late-onset patients with obsessive-compulsive disorder Int J Neuropsychopharmacol 14 606 617 21232166 10.1017/S1461145710001604 1:CAS:528:DC%2BC3MXlslWmsb4%3D
21. Bertoldo A, Cobelli C. Physiological modelling of positron emission tomography images. In: Carson E, Cobelli C, editors. Modelling methodology for physiology and medicine. San Diego: Academic Press; 2001. p. 179-211.
22. Carson RE. Parameter estimation in positron emission tomography. In: Phelps ME, Mazziotta JC, Schelbert HR, editors. Positron emission tomography and autoradiography: principles and applications for the brain and heart. New York: Raven Press; 1986. p. 347-90.
23. 11C](+)McN-5652: assessment of methods J Cereb Blood Flow Metab 20 253 262 10698061 10.1097/00004647-200002000-00005 1:CAS:528:DC%2BD3cXhs1alur4%3D
24. 11C]McN 5652 J Nucl Med 41 1465 1477 10994724 1:CAS:528: DC%2BD3cXntFOht7g%3D
25. 15O: validation by comparison with 2-dimensional PET J Nucl Med 49 50 59 18077532 10.2967/jnumed.107.044008